Founded in 2004 by Mr. Hironori Ando (CEO) and Dr. Kazuo Sakurai (CSO), NapaJen is a privately held bio-therapeutics company with HQ offices in the San Francisco Bay Area and R&D operations and scientific roots in Japan. Initially serial seed funded by Mitsui Global Investments (MGI) in February 2014, NapaJen became the recipient of a major series A investment from Innovation Network Corporation of Japan (INCJ) and MGI for development towards market entry. In December 2016 NapaJen completed series B financing lead by INCJ in partnership with MGI, Nissay Capital Co., Ltd. and Mizuho Capital Co., Ltd. In addition to seasoned executive support from its investors, NapaJen is guided by a group of distinguished international clinical, scientific and pharmaceutical advisors and consultants on its path to commercial goals.